NARA Discovery
Article Details
← Back to Search Results
Journal Article

Inverted human umbilical artery as a 3D scaffold for sciatic nerve regeneration in rats

Flore-Anne Lecoq; Laurence Barnouin; Ludovic Ardouin; Daniel Hartmann; Laurent Obert
Cell and Tissue Banking · Vol. 23, Issue 4 · pp. 909-922 · 2022

Abstract

Treatment of peripheral nerve injuries (PNIs) remains a challenge. Interposing a graft delivers better regenerative outcomes. Autografts present major drawbacks which have given rise to the development of alternatives such as artificial scaffolds, some of which are very promising. This study was designed to investigate the potential use of an inverted human umbilical cord artery (iHUA) as a 3D scaffold nerve chamber, for nerve regeneration after transection of the sciatic nerve (SN) in rats. Rats underwent surgical SN transection in their right hindlimb, followed by suture of the device at the resected stumps. Local tolerance, insert biodegradability and nerve reconstruction over time were thoroughly studied by histopathological and morphometric analysis, completed by functional test assessment of sensitivity and motricity recovery. We have demonstrated that nerve reconstruction in the presence of an iHUA insert is effective. The device is well tolerated and highly biodegraded. Although the regenerated nerve is still immature at the end of our study, signs of sensitivity and partial functional recovery were witnessed, confirming our histological findings. Our results support the potential clinical use of iHUA as a 3D scaffold to bridge nerve discontinuity and guide axonal regrowth in selected cases of PNIs.

Bibliographic Information

JournalCell and Tissue Banking
PublisherSpringer
Publication Date2022-12-01
Publication Year2022
Volume23
Issue4
Pages909-922
Document TypeJournal Article
eISSN1573-6814
DOI10.1007/s10561-022-10006-8

Access Information

NARA Access Coverage2000-01-01~Current
Journal Homepagehttps://www.springer.com/journal/10561
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.